Market Dashboard
- You are here:
- Home
- Markets
- Market Dashboard
- Lupin Ltd.
NSE Symbol: | BSE Code: | ISIN: | Sector:
- Add to Portfolio
- Add to Watchlist
- Add to Alert
- Add to Message
| Change | Change % |
| -9.80 | -1.19% |
Updated:08 Jun, 2023, 15:54 PM IST |
|
| Change | Change % |
| -10.10 | -1.23% |
Updated:08 Jun, 2023, 16:01 PM IST |
|
Day's Range
52 Wk Range
Compare Price performance of vs. Peer Companies
From sector
Compare with Peers on Key Fundamentals and Financials
- SUNPHARMA
-2.61% - DIVISLAB
-1.05% - CIPLA
-0.70% - DRREDDY
0.27% - CADILAHC
-0.48% - ABBOTINDIA
-0.85% - ALKEM
1.69% - AUROPHARMA
0.66% - LUPIN
-1.23% - TORNTPHARM
0.45% - BIOCON
-0.74% - GLAXO
-1.41% - GLENMARK
2.69% - PFIZER
0.20% - JBCHEPHARM
0.81% - SANOFI
-1.62% - PEL
-0.32% - AJANTPHARM
4.00% - NATCOPHARM
0.38% - APLLTD
6.94% - IPCALAB
-1.49% - ERIS
0.86% - ASTRAZEN
-0.14% - MERCK
-3.86% - GRANULES
-0.81% - CAPLINLABS
4.46% - FDC
0.98% - HIKAL
-2.55% - LAURUSLABS
1.45% - NEULANDLAB
-1.50%
's Latest Research Report
| Brokerage/Analyst | Report Date | Call | Price@Call | Target | Current Status | Report |
|---|---|---|---|---|---|---|
| Nirmal Bang - |
27-11-2019 | Buy | 792.60 | 824.00 | Closed | Details |
| Edelweiss - |
19-07-2019 | Buy | 746.30 | 900.00 | Closed | Details |
| Nomura - |
25-04-2019 | Buy | 867.80 | 1017.00 | Closed | Details |
| HDFC Securities - |
16-05-2018 | Buy | 763.00 | 1190.00 | Closed | Details |
| Credit Suisse - |
24-04-2017 | Buy | 1365.75 | - | Closed | Details |
More from Research Reports »
Lupin's Key Fundamentals
| Parameter | Values |
|---|---|
| Market Cap (in ₹ Cr.) | 36,742.95 |
| Earning Per Share (EPS TTM) (₹) | 34.04 |
| Price To Earnings (P/E) Ratio | 23.85 |
| Book Value Per Share (₹) | 344.47 |
| Price To Books (P/B) Ratio | 2.36 |
| EBIT Margin (%) | 18.11 |
| PAT Margin (%) | 13.33 |
| ROCE (%) | 11.72 |
| PAT Growth (%) | -57.19 |
| Total Debt to Equity (D/E) Ratio | 0.00 |
More from Key Fundamentals »
Lupin's Financial Summary
| Parameter | MAR'18 (₹ Cr.) |
MAR'17 (₹ Cr.) |
YoY %Change |
|---|---|---|---|
| Balance Sheet: | |||
| Share Capital | 90.42 | 90.32 | 0.11% |
| Total Non-Current Liabilities | 559.83 | 502.39 | 11.43% |
| Total Current Liabilities | 2,336.21 | 2,565.61 | -8.94% |
| Total Liabilities | 18,681.00 | 17,848.24 | 4.67% |
| Total Non-Current Assets | 9,963.55 | 8,597.47 | 15.89% |
| Currents Investments | 232.59 | 2,112.00 | -88.99% |
| Cash and Bank | 110.96 | 172.84 | -35.80% |
| Total Current Assets Excluding Current Investments | 8,484.86 | 7,138.77 | 18.86% |
| Total Assets | 18,681.00 | 17,848.24 | 4.67% |
| Profit and Loss: | |||
| Gross Sales | 10,088.18 | 12,753.15 | -20.90% |
| Net Sales | 10,088.18 | 12,753.15 | -20.90% |
| PBIDT (Excl OI) | 2,085.86 | 4,486.12 | -53.50% |
| PAT | 1,344.66 | 3,141.33 | -57.19% |
More from Financial Summary »
Lupin's Shareholding Pattern
| Description | Percent of Share (%) |
|---|---|
| Promoters | 46.93 |
| Individuals | 7.97 |
| Institutions | 16.53 |
| FII | 27.52 |
| Govt. | 0.00 |
| Others | 1.05 |
More from Holding Pattern »
Lupin held by Mutual Fund Schemes
More from Mutual Fund Holding »
's Futures and Options Quotes
| Contract Expiry Date |
Type | Current price | Change | Change % | Premium / Discount |
|---|---|---|---|---|---|
| LUPIN 29-06-2023 |
FUTSTK |
815.05 | -7.45 | -0.91% | 3.20 |
| LUPIN 27-07-2023 |
FUTSTK |
816.50 | -8.85 | -1.07% | 4.65 |
| LUPIN 31-08-2023 |
FUTSTK |
822.00 | -6.85 | -0.83% | 10.15 |
More from Futures and Options Quotes »
Lupin is a pharmaceutical company headquartered in Mumbai. Lupin is the second largest Indian pharmaceutical company by sales. It is the 4th largest generics company globally by market capitalization and the 6th largest generics pharmaceutical company globally by sales, as of March 31, 2017. Lupin logged a net profit of Rs 3,141 crore over revenue of Rs 12,753 crore in FY17. As of September 2017, Lupin's promoter group held a 46.80 per cent stake in the drug maker while the remaining 53.20 per cent was with the public.
Lupin is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds a global leadership position in the Anti-TB segment. The US remains Lupin's largest and most important market with 48 per cent share of total revenues. In FY17, Lupin's US revenues surpassed the $1 billion mark, closing at $1,207 million, a year-on-year growth of 37 per cent. With a market share of 3.3 per cent, Lupin is the 6th largest player in the Indian Pharmaceutical Market (IPM).
Lupin shares
The shares are traded with symbol LUPIN on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
History
Lupin was founded in 1968 by Dr Desh Bandhu Gupta. The company was named after the Lupin flower because of the inherent qualities of the flower.
BackgroundIn March 2016, Lupin completed its acquisition of US-based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS). This strategic acquisition enhanced Lupin's scale in both the US generics and brands market as well as broadened its pipeline in dermatology, controlled substance products and other niche generics.
Registered office
Kalpataru, Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East), Mumbai, Maharashtra-400055